Mercedes-Benz to Launch Advanced Urban Self-Driving System in the U.S., Challenging Tesla FSD 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Nvidia Unveils Rubin Platform to Power Next Wave of AI Infrastructure 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Tesla UK Sales Slide as Competition Intensifies, While BYD Surges in Electric Vehicle Market 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
Samsung to Double AI-Powered Mobile Devices with Google Gemini in Global AI Race 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
ROCKVILLE, Md., Oct. 23, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its third quarter 2017 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, November 1st. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
Individuals interested in accessing the live audio webcast of the teleconference may do so at http://www.sucampo.com/investors/events-presentations/ and should log on 10 to 15 minutes before the teleconference begins to download any software required. Presentation slides will be available via the webcast link. A replay of the webcast will also be available on Sucampo’s website for several days after the live event. Alternatively, individuals may dial 888-636-8238 (domestic) or 484-747-6635 (international) and use passcode 97804103. A replay of the teleconference will be available by dialing 855-859-2056 (domestic) or 404-537-3406 (international), passcode 97804103, approximately two hours after the teleconference concludes. The archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a 2-hydroxypropyl-beta-cyclodextrin product with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2b/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1, a rare progressive genetic disorder. VTS-270 also has been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP1-x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
[email protected]
